{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
riboflavin phosphate
to a specific field?
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2021
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2019
Source:
M018
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02234869: Phase 4 Interventional Withdrawn Relapsing Multiple Sclerosis
(2014)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2024)
Source:
NDA218614
(2024)
Source URL:
First approved in 2024
Source:
NDA218614
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2023)
Source:
NDA217388
(2023)
Source URL:
First approved in 2023
Source:
NDA217388
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2023)
Source:
NDA217225
(2023)
Source URL:
First approved in 2023
Source:
NDA217225
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2022)
Source:
NDA215515
(2022)
Source URL:
First approved in 2022
Source:
NDA215515
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2021)
Source:
NDA214012
(2021)
Source URL:
First approved in 2021
Source:
NDA214012
Source URL:
Class:
NUCLEIC ACID
